跳转至内容
Merck
CN

1341001

USP

吲哚美辛

United States Pharmacopeia (USP) Reference Standard

别名:

1-(4-氯苯甲酰基)-5-甲氧基-2-甲基-3-吲哚乙酸

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C19H16ClNO4
CAS号:
分子量:
357.79
Beilstein:
497341
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

indomethacin

制造商/商品名称

USP

应用

pharmaceutical (small molecule)

包装形式

neat

SMILES字符串

COc1ccc2n(c(C)c(CC(O)=O)c2c1)C(=O)c3ccc(Cl)cc3

InChI

1S/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23)

InChI key

CGIGDMFJXJATDK-UHFFFAOYSA-N

基因信息

正在寻找类似产品? 访问 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Indomethacin USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Indomethacin Capsules
  • Indomethacin Extended-Release Capsules
  • Indomethacin for Injection
  • Indomethacin Oral Suspension
  • Indomethacin Sodium
  • Indomethacin Suppositories

生化/生理作用

环加氧酶 (COX) 抑制剂,对 COX-1 的选择性相对较高。

分析说明

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他说明

Sales restrictions may apply.

象形图

Skull and crossbones

警示用语:

Danger

危险声明

预防措施声明

危险分类

Acute Tox. 1 Oral

储存分类代码

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Taco J Blokhuis et al.
Clinical orthopaedics and related research, 467(2), 526-530 (2008-09-30)
Heterotopic ossification is a well-known complication after fixation of an acetabular fracture. Indomethacin and radiation therapy are used as prophylaxis to prevent heterotopic ossification. It is unclear, however, whether either is superior, although this may relate to lack of power
Ramesh Chennupati et al.
PloS one, 9(7), e102264-e102264 (2014-07-18)
Argininosuccinate synthetase (ASS) is essential for recycling L-citrulline, the by-product of NO synthase (NOS), to the NOS substrate L-arginine. Here, we assessed whether disturbed arginine resynthesis modulates endothelium-dependent vasodilatation in normal and diabetic male mice. Endothelium-selective Ass-deficient mice (Assfl/fl/Tie2Cretg/- = Ass-KOTie2) were
L J Jones et al.
Archives of disease in childhood. Fetal and neonatal edition, 96(1), F45-F52 (2010-09-30)
To evaluate the effects of indomethacin or ibuprofen compared with placebo on closure, morbidity and mortality in preterm infants <37 weeks' gestation with echocardiographically and/or clinically important patent ductus arteriosus (PDA) at >24 h of life. MEDLINE, EMBASE, Cochrane Central
Brian J Krieg et al.
Journal of pharmaceutical sciences, 103(11), 3473-3490 (2014-09-13)
Development of an oral in vivo predictive dissolution medium for acid drugs with a pKa in the physiological range (e.g., Biopharmaceutics Classification System Class IIa) requires transport analysis of the complex in vivo CO2 /bicarbonate buffering system. In this report
Roland Neumann et al.
Neonatology, 102(1), 9-15 (2012-03-15)
Pharmacological closure of patent ductus arteriosus (PDA) is commonly achieved by intravenous (IV) administration of ibuprofen or indomethacin. Occasionally, oral ibuprofen is used for PDA treatment although its efficacy and safety are unclear. To systematically review randomized and quasi-randomized trials

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门